Details

Autor(en) / Beteiligte

• Saravolatz, Louis D.
• Bern, Caryn
• Adler-Moore, Jill
• Berenguer, Juan
• Boelaert, Marleen
• den Boer, Margriet
• Davidson, Robert N.
• Figueras, Concepcion
• Gradoni, Luigi
• Kafetzis, Dimitris A.
• Ritmeijer, Koert
• Rosenthal, Eric
• Royce, Catherine
• Russo, Rosario
• Sundar, Shyam
• Alvar, Jorge

Titel

Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis

Ist Teil von

• Clinical infectious diseases, 2006-10, Vol.43 (7), p.917-924

Ort / Verlag

Chicago, IL: The University of Chicago Press

Erscheinungsjahr

2006

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.